209 related articles for article (PubMed ID: 35766058)
21. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
22. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
23. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
24. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Abdel-Mannan OA; Manchoon C; Rossor T; Southin JC; Tur C; Brownlee W; Byrne S; Chitre M; Coles A; Forsyth R; Kneen R; Mankad K; Ram D; West S; Wright S; Wassmer E; Lim M; Ciccarelli O; Hemingway C; Hacohen Y;
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021056
[TBL] [Abstract][Full Text] [Related]
25. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
26. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
27. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
28. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
29. Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.
Sá MJ; Sequeira L; Ferro D; Marcolino A; Rocha AL; Seabra M; Mendonça T; Abreu P; Guimarães J; Macedo A
Mult Scler Relat Disord; 2021 Sep; 54():103091. PubMed ID: 34246020
[TBL] [Abstract][Full Text] [Related]
30. The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis.
Topic A; Vasic M; Markovic B; Milinkovic N; Dincic E
Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):157-161. PubMed ID: 36093923
[TBL] [Abstract][Full Text] [Related]
31. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
Braune S; Rossnagel F; Dikow H; Bergmann A;
BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
[TBL] [Abstract][Full Text] [Related]
32. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
33. Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM.
Gisela Z; Carla P; Josefina B; Tomas I; Lucia B; Pappolla A; Miguez J; Patrucco L; Cristiano E; Norma D; Verónica T; Carlos V; Leila C; Alonso R; Garcea O; Silva B; Celica Y; Marrodan M; Gaitán MI; Correale J; Marcos B; Luciana L; Anibal C; Emanuel S; Eduardo K; Judith S; Dario T; Javier H; Pedro N; Felisa L; Pablo LA; Susana L; Patricio B; Raul P; Adriana C; Alejandra M; María Eugenia B; Contentti Edgar C; Amelia AP; Carolina M; Mariano C; Luciano R; Matias K; Eduardo K; María Celeste C; Maria Laura M; Santiago T; Mariela C; Fatima PC; Andres B; Geraldine L; Alonso Serena M; Juan Ignacio R; Marcos S;
Neurol Res; 2023 Feb; 45(2):112-117. PubMed ID: 36184106
[TBL] [Abstract][Full Text] [Related]
34. Untreated patients with multiple sclerosis: A study of French expert centers.
Moisset X; Fouchard AA; Pereira B; Taithe F; Mathey G; Edan G; Ciron J; Brochet B; De Sèze J; Papeix C; Vermersch P; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Laplaud D; Berger E; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Créange A; Camdessanché JP; Bakchine S; Maurousset A; Hankiewicz K; Pottier C; Maubeuge N; Dimitri Boulos D; Nifle C; Vukusic S; Clavelou P;
Eur J Neurol; 2021 Jun; 28(6):2026-2036. PubMed ID: 33650261
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
36. A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands.
Michels RE; Peters ML; Schiffers KM; Bouma PA; Hengstman GI; van Munster CE; Zeinstra E; Voer G; Krol M
J Comp Eff Res; 2021 Feb; 10(2):93-100. PubMed ID: 33275036
[No Abstract] [Full Text] [Related]
37. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
Al-Keilani MS; Almomani BA
Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
[TBL] [Abstract][Full Text] [Related]
38. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.
Meca-Lallana J; García-Merino JA; Martínez-Yélamos S; Vidal-Jordana A; Costa L; Eichau S; Rovira À; Brieva L; Agüera E; Zarranz AR
Neurodegener Dis Manag; 2021 Jun; 11(3):251-261. PubMed ID: 33966475
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
40. Multiple sclerosis in the elderly: a retrospective cohort study.
Zinganell A; Göbel G; Berek K; Hofer B; Asenbaum-Nan S; Barang M; Böck K; Bsteh C; Bsteh G; Eger S; Eggers C; Fertl E; Joldic D; Khalil M; Langenscheidt D; Komposch M; Kornek B; Kraus J; Krendl R; Rauschka H; Sellner J; Auer M; Hegen H; Pauli FD; Deisenhammer F
J Neurol; 2024 Feb; 271(2):674-687. PubMed ID: 37855871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
